1g versus 2g Daily Intravenous Ceftriaxone in the Treatment of Community Onset Pneumonia – a propensity score analysis of data from a Japanese multicenter registry

Shinya Hasegawa
Tokyo Toritsu Tama Sogo Iryo Center

Ryuichi Sada
Koeki Zaidan Hojin Tenri Yorozu Sodanjo Byoin Ikoi no Ie

Makito Yaegashi
Kameda Medical Center

Konosuke Morimoto
Nagasaki Daigaku

Takahiro Mori (✉ takahiromori@outlook.com)
Tsukuba Daigaku Igaku Iryokei  https://orcid.org/0000-0003-0216-2284

Research article

Keywords: ceftriaxone, community-onset pneumonia, community-acquired pneumonia, cure rate, non-inferiority

Posted Date: October 4th, 2019

DOI: https://doi.org/10.21203/rs.2.10421/v4

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on December 26th, 2019. See the published version at https://doi.org/10.1186/s12879-019-4552-8.
Abstract

Objectives: Community-onset pneumonia (COP) is a supplant concept of community acquired pneumonia, which includes the previous classification of healthcare-associated pneumonia. Although ceftriaxone (CRO) is one of the treatment choices for COP, it is unclear whether 1 or 2 g CRO daily has better efficacy. We compared the effectiveness of 1 g with 2 g of CRO for COP treatment. We hypothesized that 1 g CRO would show non-inferiority over 2 g CRO. Methods: This study was an analysis of prospectively registered data from four Japanese hospitals for patients with COP (the Adult Pneumonia Study Group-Japan: APSG-J). Subjects who were initially treated solely with 1 or 2 g of CRO were enrolled. The propensity score was estimated from the 33 pre-treatment variables, including age, sex, weight, pre-existing comorbidities, prescribed drugs prior to admission, risk factors for aspiration pneumonia, vital signs, laboratory data, and findings from chest x-rays. The primary endpoint was the cure rate, for which a non-inferiority analysis was performed with a margin of 0.05. In addition, we performed three sensitivity analyses; using data limited to the group in which CRO solely was used until the completion of treatment, using data limited for inpatient cases, and including a generalised linear mixed-effect logistic regression analysis to assess the primary outcome after adjusting for random hospital effects. Results: Of the 3,817 adult subjects with pneumonia who were registered in the APSG-J study, 290 and 216 were initially treated solely with 1 or 2 g of CRO, respectively. Propensity score matching was used to extract 175 subjects in each group. The cure rate was 94.6% and 93.1% in the 1 and 2 g CRO groups, respectively (risk difference, 1.5%; 95% confidence interval, −3.1 to 6.0; p = 0.009 for non-inferiority). The results of the sensitivity analyses were consistent with the primary result. Conclusions: The propensity score-matched analysis of multicenter cohort data from Japan revealed that the cure rate for COP patients treated with 1 g CRO was non-inferior to that of patients treated with CRO.

Background

Community-acquired pneumonia (CAP) is one of the most common infectious diseases and is a leading cause of morbidity and mortality worldwide [1,2]. The Infectious Diseases Society of America (IDSA) guidelines recommend that either respiratory quinolone or beta-lactam plus azithromycin to be used as a first line therapy for CAP; Ceftriaxone (CRO) is one of the recommended regimens among beta-lactam antibiotics [2,3].

The Sanford Guide for Antimicrobial Therapy recommends that the dose of CRO should be 1-2 g daily to treat pneumonia [4]. However, it is unclear whether 1 or 2 g of CRO daily is better. To date there have been a few studies comparing the effectiveness of 1 and 2 g CRO for CAP. In one study CRO was used for pneumonia in addition to other community acquired infections such as urinary tract infections or cellulitis [5]. Another study compared 1 g CRO not only with 2 g CRO but also with other agents [6]; with such designs it is not possible to determine the optimal dose of CRO for pneumonia. Studies have shown that the cost of treatment for pneumonia is less expensive with 1 g of CRO [7], and the risk of gallstone formation is lowered because more than 2 g or 40 mg/kg daily of CRO is one of the risk factors of gallstone formation (odds ratio: 11.9, 95% confidence interval [CI]: 2.6–54.2) [8]. In addition, optimization
of antimicrobial dosing is an essential part of antimicrobial stewardship [9]. Conversely, we need to be very cautious about the effectiveness of antibiotics for the treatment of pneumonia, as the proportion of elderly people in populations is increasing dramatically worldwide, and old age is thought to be an independent risk factor for mortality associated with CAP [10,11].

Community-onset pneumonia (COP) is a supplant concept of CAP which includes the previous classification of healthcare-associated pneumonia (HCAP). The hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) guidelines in 2016 indicate that patients with HCAP, such as those with CAP, frequently present from the community and are initially cared for in emergency departments [12]. Additionally, these guidelines revealed that HCAP, defined as a high risk category for multiple drug resistance in the HAP / VAP guidelines in 2005, could be included in the CAP.

The aim of our study was to compare the effectiveness of 1 and 2 g CRO as treatment for COP, using data from a Japanese multicenter registry. We hypothesized that 1 g CRO would show non-inferiority over 2 g CRO for treatment of patients with COP.

**Methods**

**Setting and study population**

This propensity score-matching study was a sub-study of the Adult Pneumonia Study Group-Japan (APSG-J) study; this study aimed to compare the effectiveness of 1 g CRO treatment to 2 g of COP treatment for adult patients. The APSG-J study was initiated after obtaining approval by the Institutional Review Boards (IRBs) of all five study hospitals, namely the Institute of Tropical Medicine at Nagasaki University, Ebetsu City Hospital, Kameda Medical Center, Chikamori Hospital, and Juzenkai Hospital. Written consent from participants was waived by all IRBs because of the study's observational nature, without any deviation from the current medical practice. The study was conducted on all of the four main islands of Japan from September 2011 through August 2014.

The APSG-J study collected data from adult patients with pneumonia prospectively to elucidate trends in COP and its aetiologies in the aging society [13]. Eligible patients were enrolled in the APSG-J study if they fulfilled all of the following criteria: patients 1) ≥ 15 years; 2) exhibited symptoms compatible with pneumonia (e.g., fever, cough, sputum, pleuritic chest pain, and dyspnoea); and 3) displayed new pulmonary infiltrates on chest X-ray images (CXR) or computed tomography scans that were consistent with pneumonia. Patients were enrolled from both inpatient and outpatient services. In this study, subjects who were initially treated solely with 1 or 2 g CRO were enrolled.

**Assessment of outcomes**

The primary outcome was the cure rate, which was defined based on the state on discharge described in the patient's record; this was assessed using the frequency of cured patients in each group. The states in
the record included cure, stable condition, exacerbation, death, hospital transfer, and others. Secondary outcomes included in-hospital mortality, the duration of antibiotics, and length of hospital stay between the two groups.

**Data preparation and sample size estimation**

All statistical analyses were performed with the R 3.2.3 software for statistical computing (https://www.r-project.org/); the add-on packages “mice” for multiple imputation and “matching” for propensity score matching were used [14,15]. These analyses were conducted according to the methods used in a previous propensity-score matching study [16]. The primary analysis of the cure rate was conducted using a non-inferiority analysis with a one-sided alpha level of 0.05. The non-inferiority margin was set at an absolute value of 5.0%, based on the Food and Drug Administration non-inferiority clinical trial guidance to determine the margin for pneumonia, and two previous clinical trials [5,6,17]. We chose the Farrington and Manning test because propensity-score matching would only give us the same sample size for the two groups, and the Farrington and Manning test requires that the same sample size be enrolled in the two groups. The sample size for the primary outcome was calculated based on the previous randomized control trials, which suggested that the cure rate in the 1 and 2 g CRO groups would be 92% and 87%, respectively [5,6]. We calculated that a sample of 161 patients per group would give the study 90% power to detect non-inferiority for 1 g CRO treatment.

Apart from the primary outcome of the main analysis, we also used a two-sided alpha level of 0.05, and differences were considered significant if p-values were \( \leq 0.05 \). The survival of patients was shown using a Kaplan-Meier survival curve, and adjusted hazard ratios (aHRs) were calculated using multivariable Cox proportional hazards regression analyses. As there were several missing values observed (Supplementary table 1), we used multiple imputation by employing chained equations to complement all missing values for each study variable. Thereby we generated 25 datasets with 20 iterations.

**Propensity score matching**

A logistic regression analysis was used to estimate the propensity scores, which were then utilized to predict the efficacy of the use of 1 g over 2 g of CRO. This prediction incorporated 33 pre-treatment covariates, including age, sex, weight, pre-existing comorbidities, if the medical histories were consistent with CAP or not, prescribed drugs prior to admission (specifically oral steroids, benzodiazepines, and anti-acid drugs), risk factors for aspiration pneumonia, vital signs (respiratory rate, systolic blood pressure, heart rate, and body temperature), laboratory data (haematocrit and levels of blood urea nitrogen, sodium, glucose, and albumin), and findings from CXRs (pleural effusion). Propensity score matching was conducted for the selected subjects on a pairwise basis after all propensity scores across the imputed datasets had been averaged and logit-transformed. The match caliper was set to 0.2. We used absolute
standardized mean differences (ASMD) for all variables included in the propensity score estimation to assess the match balance; an ASMD of < 0.1 was defined as an appropriate match balance.

**Sensitivity analysis**

We performed three sensitivity analyses as follows. All the outcomes were reassessed using data limited to the group in which CRO solely was used until the completion of treatment. We evaluated the primary outcome exclusively for inpatient cases, given that the treatment environment (e.g., inpatient vs. outpatient) might influence mortality. Finally, we included a generalised linear mixed-effect logistic regression analysis to assess the primary outcome after adjusting for random hospital effects, since antibiotic selection preferences might differ between the hospitals.

**Results**

**Baseline characteristics of the participants before and after propensity score matching**

Of the 3,817 adult subjects with pneumonia who were registered in the APSG-J study, 290 and 216 were initially treated solely with 1 or 2 g of CRO, respectively. Propensity score matching was employed to finally extract 175 subjects in each group (Figure 1, Table 1, Supplementary Figure 1).

**Primary outcome for patients after propensity score matching**

Overall, the cure rate was 94.6% in the 1 g CRO group and 93.1% in the 2 g CRO group (risk difference, 1.5%; 95% CI, −6.6 to 3.6; p = 0.009 for non-inferiority; p = 0.572 for superiority) (Table 2).

**Secondary outcomes for patients after propensity score matching**

When considering all of the propensity score-matched subjects, the length of hospital stay in the 1 g CRO group (17 days [95% CI: 14-21 days]) was significantly shorter than that in the 2 g CRO group (26 days [95% CI: 22-30 days]; p < 0.001). Duration of antibiotic treatment in the 1 g CRO group was also significantly shorter (8 days [95% CI: 8-9 days]) than that in the 2 g CRO group (10 days [95% CI: 9-10 days]; p = 0.002). The in-hospital mortality rate did not significantly differ between the 1 (4.7% [95% CI: 1.5-8.0%]) and 2 g CRO groups (4.0% [95% CI: 1.1-6.9%]; p = 0.740) (Table 2). Survival analysis of the propensity score-matched subjects revealed a similar survival time in the two groups. Specifically, the aHR for mortality in the 1 g CRO group vs. the 2 g CRO group was 1.58 (95% CI: 0.56-4.43) (p = 0.385) (Figure 2).
Results of the sensitivity analyses

For the patients in which treatment was solely CRO for the duration of treatment, we could not ascertain an appropriate match using the same variables for the main-analysis; thus, we decreased the number of variables used, limiting the sample size to 94 subjects in each group. The cure rate was 88.9% (95% CI: 82.3-95.4%) in the 1 g CRO group and 91.5% (95% CI: 85.7-97.2%) in the 2 g CRO group (p = 0.549 for superiority). The difference in the length of hospital stay was significantly shorter in the 1 g CRO group (18 days [95% CI: 14-22 days]) than that in the 2 g CRO group (26 days [95% CI: 21-32 days]; p = 0.007). The duration of antibiotics treatment and the in-hospital mortality rate did not significantly differ between the two groups (Table 3). The analysis using only inpatient cases produced similar results (1 g CRO group: 95.4% [95% CI: 91.8-99.0 %] vs. 2 g CRO group: 90.7% [95% CI: 85.8-95.6 %]; p = 0.127 for superiority). Finally, the analysis using the random hospital effect as a sensitivity measure also supported the above finding (odds ratio, 0.77 [95% CI: 0.32-1.90], p = 0.576).

Discussion

In this study, the cure rate for COP patients treated with 1 g CRO was non-inferior compared to those treated with 2 g CRO. The aim of this study was to show that a smaller antibiotic dose was non-inferior to the higher dose; additionally, we wanted to demonstrate that a smaller dose could potentially decrease the dose-dependent adverse effects, cost, and the risk of antimicrobial resistance [7,8,17]. Actually, optimization of antibiotics dose is one of the major aims in the era of antimicrobial stewardship [9] in order to make resistant pathogens less likely to occur. However, many clinicians and researchers alike may consider the difference between treatment with 1 g and that with 2 g CRO as subtle, regardless of the fact that, to our knowledge, high-quality evidence available to this effect is unavailable. Although a few studies recently evaluated the effectiveness of 1 and 2 g CRO and some other agents for CAP [18,19], the numbers of patients enrolled was small, leading to a lack of power [5,6]. Our study will further enhance the results of the previous clinical trials, given that our study was performed with adequate power.

We were aware that determining the non-inferiority margin should be prudent and cautious, and it is important that the margin is set appropriately based on the findings from previous studies [17,20]. We set 5% as the non-inferiority margin for the cure rate based on the findings from previous clinical trials [5,6]. There is a trade-off relationship between the non-inferiority margin and the potential benefits, which in our study included the fewer side effects and lower cost of antibiotics. We believe that the 5% non-inferiority margin was a reasonable value from a clinical standpoint.

The length of hospital stay and duration of antibiotics were significantly shorter in the 1 g CRO group based on the main-analysis, and the sub-analysis showed that the length of hospital stay was also significantly shorter in the 1 g CRO group, in which the treatment was completed exclusively using 1 g CRO. As these results were unexpected, we conducted a generalised linear mixed-effect logistic regression model analysis, and confirmed that the length of the hospital stay and duration of antibiotics were not influenced by random hospital effects. These results might be explained by the fact that a lower dose of
antibiotics might lead to fewer side effects, because a variety of adverse events related to CRO were reported [21]. We are, however, uncertain whether all of those adverse events, with the exception of gallstones, were dose-dependent [8,22]. In this study, we did not have information regarding the side effects caused by antibiotic treatment reported in the various hospitals. Another possible explanation for our findings is that patients’ socioeconomic status (SES) in the 1 g CRO group could have been higher compared to those in the 2 g CRO group. The higher the SES and the fewer problems encountered by the family in preparing a well-ordered environment or nursing home for the patient, the greater the chances might be that the patient would be discharged earlier. These factors suggest that our results should be interpreted prudently.

This study was subject to several limitations. First, this study was designed as non-inferiority trial, and the margin was set retrospectively. However, we discussed the appropriateness of the non-inferiority margin carefully. Second, this was an observational study, and the information was not collected regarding the factors related to SES. Third, we were unable to make comparisons between the two groups based on the sputum cultures. Our results may be associated with differences in bacterial aetiology, so their interpretation requires some caution. However, we could not include culture results as pre-treatment variables, as these results were obtained after treatment was initiated, i.e., we usually prescribed antibiotics without any significant sputum culture results since approximately three days are required to identify pathogens. The frequency of pneumonia related bacteria in the APSG-J study population was previously reported [13]. Fourth, the overall in-hospital mortality rate in our study was lower (4.3%) than that of a COP mortality (11.5%) in the APSG-J study [13]. This might reflect the situation, in which our participants might be healthier than typical COP patients.

Our study had several strengths despite these limitations. To our knowledge, this was the first study to investigate the body weight of the patient as well as the optimal dose of CRO. The mechanism in which CRO is distributed throughout the body depends on the patients’ volume, so we would not be able to investigate the effectiveness of CRO without also taking body weight into account. Second, we used prospectively collected multicenter registry data; multiple imputation and propensity score matching was conducted to increase the robustness of the analysis. Additionally, many covariates were analysed to increase the consistency of the results. We chose a variety of covariates not only based on major criteria such as the CURB-65 or Pneumonia Severity Index [23,24], but we also included factors associated with pneumonia mortality [25-27]. Finally, our study had sufficient power as discussed above, while one of the major criticisms of the previous studies was the insufficient power. This study, therefore, provided additional meaningful insights regarding the optimal dose of CRO for the treatment of COP.

**Conclusions**

In this propensity score-matched analysis of multicenter cohort data, the cure rate of COP patients treated with 1 g CRO was non-inferior to those treated with 2 g CRO. Our study offers useful insights regarding the optimal dose of CRO for patients with COP. Further studies, for example randomized control studies with adequate power are needed to strengthen the evidence regarding this treatment alternative.
Abbreviations
CAP, community-acquired pneumonia; IDSA, Infectious Diseases Society of America; CRO, ceftriaxone; COP, community-onset pneumonia; HCAP, healthcare-associated pneumonia; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; APSG-J, Adult Pneumonia Study Group-Japan; IRBs, Institutional Review Boards; CXR, chest X-ray images; aHRs, adjusted hazard ratios; ASMD, absolute standardized mean differences; SES, socioeconomic status.

Declarations

Ethics approval and consent to participate

The APSG-J study adhered to the Guidelines for Ethical Aspects in Epidemiological Study (MHLW, 2008). Ethical approval was obtained by the Institutional Review Boards at all of the five study hospitals, namely the Institute of Tropical Medicine at Nagasaki University, Ebetsu City Hospital, Kameda Medical Center, Chikamori Hospital, and Juzenkai Hospital.

This study was of noninterventional nature and did not include primary data collection (i.e., was based on published secondary data only). Therefore, ethic committee or institutional review board approval was not required. Data used were taken from published cohort trials, which were conducted according to the principles of the Declaration of Helsinki and with informed consent from participants. The APSG-J study was approved by the Institutional Review Boards in the Tropical Medicine at Nagasaki University, and the committee’s reference number was 11063070.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are not publicly available due to other ongoing research projects using the datasets, but could be available from the corresponding author on reasonable request.

Competing interests

M.K. reports and Grants from Pfizer, speaking fee from MSD and Pfizer.
Funding

The APSG-J study was partially supported by Pfizer in the design of the study and collection.

Authors’ contributions

Literature search: S. H.

Data collection: K. M.

Study design: S. H., R. S., T. M.

Analysis of data: S. H., T. M.

Manuscript preparation: S. H., R. S., T. M.

Review of manuscript critically for important intellectual content: S. H., R. S., M. Y., K. M., T. M.

All authors read and approved the final manuscript.

Acknowledgments

The Adult Pneumonia Study Group-Japan (APSG-J) comprises Masahiko Abe 1, Takao Wakabayashi 1, Masahiro Aoshima 2, Naoto Hosokawa 3, Norihiro Kaneko 2, Naoko Katsurada 2, Kei Nakashima 2, Yoshihito Otsuka 4, Eiichiro Sando 5, Kaori Shibui 5, Daisuke Suzuki 3, Kenzo Tanaka 6, Kentaro Tochitani 3, Makito Yaegashi 5, Masayuki Chikamori 7, Naohisa Hamashige 7, Masayuki Ishida 7, Hiroshi Nakaoka 7, Norichika Aso 8, Hiroyuki Ito 8, Kei Matsuki 8, Yoshiko Tsuchihashi 8, Koya Ariyoshi 9, Bhim G. Dhouhdhel 9, Akitsugu Furumoto 9, Sugihiro Hamaguchi 1,9, Tomoko Ishifuji 9, Shungo Katoh 1,9, Satoshi Kakiuchi 9, Emi Kitashoji 9, Takaharu Shimazaki 9, Motoi Suzuki 9, Masahiro Takaki 9, Konosuke Morimoto 9, Kiwao Watanabe 9, and Lay-Myint Yoshida 10.

1 Department of General Internal Medicine, Ebetsu City Hospital, Hokkaido, Japan

2 Department of Pulmonology, Kameda Medical Center, Chiba, Japan

3 Department of Infectious Diseases, Kameda Medical Center, Chiba, Japan

4 Department of Laboratory Medicine, Kameda Medical Center, Chiba, Japan
References

[1] Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014; 371:1619-28.

[2] Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27-72.

[3] Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015; 372:1312-23.

[4] David N, George M, Henry F, et al. The Sanford Guide to Antimicrobial Therapy 2018. Virginia: ANTIMICROBIAL THERAPY, INC., 2018.

[5] Segev S, Raz R, Rubinstein E, et al. Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections. Eur J Clin Microbiol Infect Dis. 1995; 14:851-5.

[6] de Klerk GJ, van Steijn JH, Lobatto S, et al. A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections. Int J Antimicrob Agents. 1999; 12:121-7.

[7] Dietrich ES, Joseph U, Vogel F, et al. Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany. Infection. 1999; 27:148-54.

[8] Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis. 1995; 171:356-61.

[9] Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to
enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44(2):159-77.

[10] Kothe H, Bauer T, Marre R, et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J. 2008; 32:139-46.

[11] World Health Organization. Ageing and life-course. World report on ageing and health. http://www.who.int/ageing/publications/world-report-2015/en. Accessed 2 June 2019.

[12] Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63:e61-e111.

[13] Morimoto K, Suzuki M, Ishifuji T, et al. The burden and etiology of community-onset pneumonia in the aging Japanese population: A multicenter prospective study. PLoS One. 2015; 10: e0122247.

[14] Van Buuren S, Groothuis-Oudshoorn K. Multivariate imputation by chained equations. J Stat Softw. 2011; 45:1–67.

[15] Sekhon J. Multivariate and propensity score matching. J Stat Softw. 2011; 42:52.

[16] Shiraishi A, Kushimoto S, Otomo Y, et al. Effectiveness of early administration of tranexamic acid in patients with severe trauma. Br J Surg. 2017; 104:710-717.

[17] Opatowski L, Mandel J, Varon E, et al. Antibiotic dose impact on resistance selection in the community: a mathematical model of beta-lactams and Streptococcus pneumoniae dynamics. Antimicrob Agents Chemother. 2010; 54:2330-7.

[18] Zhong NS, Sun T, Zhuo C, et al. Ceftraroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015; 15:161-71.

[19] Lodise TP, Anzueto AR, Weber DJ, et al. Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftraroline fosamil or ceftriaxone in two phase III FOCUS trials. Antimicrob Agents Chemother. 2015; 59:1119-26.

[20] Althunian TA, de Boer A, Klungel OH, et al. Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. Trials. 2017; 18:107.

[21] Shalviri G, Yousefan S, Gholami K. Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre. J Clin Pharm Ther. 2012; 37:448-51.

[22] Lopez AJ, O'Keefe P, Morrissey M, et al. Ceftriaxone-induced cholelithiasis. Annals of Internal Medicine. 1991; 115:712-4.
[23] Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58:377-82.

[24] Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336:243-50.

[25] Adamuz J, Viasus D, Jiménez-Martínez E, et al. Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. J Infect. 2014; 68:534-41.

[26] Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013; 68:1057-65.

[27] Shindo Y, Ito R, Kobayashi D, et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect Dis. 2015; 15:1055-1065.

Tables

Table 1. Pre-treatment Variables for Patients Initially Treated with 1 and 2 g of Ceftriaxone Included in the Propensity Score Estimation Before and After Matching
| Variables                  | Before matching |          |          |          | After matching |          |          |          |
|---------------------------|----------------|----------|----------|----------|----------------|----------|----------|----------|
|                           |                | 1 g      | 2 g      | ASMD     | 1 g            | 2 g      | ASMD     |          |
|                           | n = 290        | n = 216  |          |          | n = 175        | n = 175  |          |          |
| Median age (y)            | 81 [71-87]     | 78 [67-85]| 0.043   |          | 79 [70-86]     | 77 [67-85]| 0.054   |          |
| Sex (Male)                | 167 (57.6)     | 146 (67.6)| 0.208   |          | 117 (66.9)     | 112 (64.0)| 0.060   |          |
| Median body weight (kg)   | 50.0           | 53.4     | 0.176    |          | 52.0           | 52.6     | 0.088   |          |
| Preexisting comorbidity   |                |          |          |          |                |          |          |          |
| Diabetes mellitus         | 77 (26.6)      | 44 (20.4)| 0.146   |          | 39 (22.3)      | 38 (21.7)| 0.014   |          |
| Malignancy                | 54 (18.6)      | 42 (19.4)| 0.021   |          | 36 (20.6)      | 33 (18.9)| 0.043   |          |
| Bronchial asthma          | 20 (6.9)       | 27 (12.5)| 0.190   |          | 18 (10.3)      | 14 (8.0)| 0.079   |          |
| COPD or bronchiectasis    | 46 (15.9)      | 69 (31.9)| 0.384   |          | 44 (25.1)      | 45 (25.7)| 0.013   |          |
| Cerebrovascular diseases  | 59 (20.3)      | 47 (21.8)| 0.035   |          | 32 (18.3)      | 33 (18.9)| 0.015   |          |
| Heart failure             | 46 (15.9)      | 47 (21.8)| 0.151   |          | 32 (18.3)      | 32 (18.3)| <0.001  |          |
| Liver disease             | 11 (3.8)       | 14 (6.5)| 0.122   |          | 9 (5.1)        | 6 (3.4)| 0.085   |          |
| Kidney disease            | 31 (10.7)      | 32 (14.8)| 0.124   |          | 20 (11.4)      | 20 (11.4)| <0.001  |          |
| Dementia                  | 35 (12.1)      | 21 (9.7)| 0.075   |          | 18 (10.3)      | 18 (10.3)| <0.001  |          |
| Prescribed drugs          |                |          |          |          |                |          |          |          |
| Prednisolone              | 8 (2.8)        | 13 (6.0)| 0.160   |          | 8 (4.6)        | 8 (4.6)| <0.001  |          |
| Anti-acid drug            | 81 (27.9)      | 79 (36.6)| 0.186   |          | 55 (31.4)      | 53 (30.3)| 0.025   |          |
| Sleeping drug             | 41 (14.4)      | 30 (13.9)| 0.007   |          | 25 (14.3)      | 25 (14.3)| <0.001  |          |
| Community-acquired pneumonia| 202 (69.7)   | 160 (74.1)| 0.101  |          | 132 (75.4)     | 129 (73.7)| 0.039   |          |
| Risk factors for aspiration pneumonia |          |          |          |          |                |          |          |          |
Overt aspiration

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
|            | 35 (12.1) | 11 (5.1) | 0.251  | 10 (5.7) | 10 (5.7) | <0.001  |

Vomiting

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
|            | 3 (1.0)  | 5 (2.3)  | 0.100   | 3 (1.7)  | 2 (1.1)  | 0.048   |

Dysphagia

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
|            | 32 (11.0) | 12 (5.6) | 0.200   | 13 (7.4) | 11 (6.3) | 0.045   |

Disturbance of consciousness

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
|            | 10 (3.4) | 9 (4.2)  | 0.038   | 7 (4.0)  | 7 (4.0)  | <0.001  |

Neuromuscular diseases

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
|            | 17 (5.9) | 5 (2.3)  | 0.180   | 3 (1.7)  | 5 (2.9)  | 0.077   |

Tube feeding

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
|            | 59 (20.3) | 47 (21.8) | 0.035  | 2 (1.1)  | 1 (0.6)  | 0.062   |

Bedridden status

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
|            | 21 (7.2) | 13 (6.0) | 0.049   | 10 (5.7) | 10 (5.7) | <0.001  |

**Vital signs upon arrival at hospital**

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
| Median RR  | 20 [18-24] | 22 [20-26] | 0.001   | 22 [18-26] | 22 [18-26] | 0.031   |

(breaths/minute)

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
| Median SBP (mmHg) | 131 [117-149] | 131 [118-152] | 0.061   | 133 [118-150] | 130 [114-150] | 0.043   |

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
| Median PR (beats/minute) | 94 [84-107] | 96 [83-110] | 0.093   | 95 [84-109] | 94 [83-110] | 0.018   |

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
| Median BT (°C) | 37.5 [36.8-38.3] | 37.5 [36.7-38.1] | 0.087   | 37.5 [36.8-38.1] | 37.5 [36.7-38.1] | 0.013   |

**Laboratory data at admission**

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
| Median Hct (%) | 37.0 [33.1-40.5] | 36.9 [33.2-40.7] | 0.023   | 37.1 [33.5-40.8] | 36.9 [33.4-41.2] | 0.026   |

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
| Median BUN (mg/dL) | 18.0 [14-24] | 17.9 [13.35-26] | 0.025   | 17.0 [13.4-25.0] | 17.0 [13.4-26.0] | 0.056   |

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
| Median serum Na (mEq/L) | 138 [135-140] | 138 [136-140] | 0.033   | 139 [135-140] | 138 [135-140] | 0.027   |

|            | Value 1 | Value 2 | p-value | Value 3 | Value 4 | p-value |
|------------|---------|---------|---------|---------|---------|---------|
| Median Glu (mg/dL) | 124 [106-153] | 129 [109-154] | 0.018   | 125 [109-157] | 131 [110-159] | 0.038   |
### Table 2. Main Analysis to Compare Primary and Secondary Outcomes for the Patients who Received 1 and 2 g of Ceftriaxone for the Treatment of Community-Onset Pneumonia

|                  | 1 g   | 2 g   | absolute difference | p         |
|------------------|-------|-------|----------------------|-----------|
| **Primary Outcome** |       |       |                      |           |
| Cure rate (%)    | 94.6  | 93.1  | 1.5 (–3.1, 6.0)      | 0.009 for non-inferiority, 0.572 for superiority |
| **Secondary Outcome** |       |       |                      |           |
| Length of hospital stay (d) | 17    | 26    | –9 (–4, –14)         | <0.001    |
| Duration of antibiotic treatment (d) | 8     | 10    | –2 (–1, –3)          | 0.002     |
| In-hospital mortality (%) |       |       | 0.7 (–3.6, 5.0)     | 0.740     |

Note: Data presented as No. (%) or median [interquartile range]. ASMD, absolute standardized mean differences; COPD, chronic obstructive pulmonary disease; RR, respiratory rate; SBP, systolic blood pressure; PR, pulse rate; BT, body temperature; Hct, hematocrit; BUN, blood urea nitrogen; Na, sodium; Glu, glucose; Alb, albumin.
Table 3. Sensitivity Analysis to Compare Primary and Secondary Outcomes for the Patients who Received 1 and 2 g of Ceftriaxone Solely for the Treatment of Community-Onset Pneumonia

|                         | 1 g (n = 94) | 2 g (n = 94) | absolute difference | p          |
|-------------------------|--------------|--------------|---------------------|------------|
| **Primary Outcome**     |              |              |                     |            |
| Cure rate (%)           | 88.9         | 91.5         | −2.6 (−6.0, 11.3)   | 0.549 for superiority |
| **Secondary Outcome**   |              |              |                     |            |
| Length of hospital stay (d) | 18          | 26          | −9 (−2, −15)       | 0.007      |
| Duration of antibiotic treatment (d) | 7          | 8           | 0 (−1, 1)         | 0.589      |
| In-hospital mortality (%) | 7.9       | 3.2         | 4.7 (−2.0, 11.3)   | 0.168      |

**Figures**
Figure 1

Selection of Participants for the Study

Patients with Community-Onset Pneumonia in APSG-J study
n = 3,817

Not initially treated with CRO alone
n = 3,311

1g of CRO, n = 290

Unmatched
n = 115

Propensity score-matched patients
n = 175

2g of CRO, n = 216

Unmatched
n = 41

Propensity score-matched patients
n = 175
Figure 2

Survival Curves for Propensity Score-Matched Subjects with Community-Onset Pneumonia Initially Treated with 1 and 2 g of Ceftriaxone

| Hospital days | 0  | 5  | 10 | 15 | 20 | 25 | 30 |
|---------------|----|----|----|----|----|----|----|
| 1g            | 175| 162| 124| 94 | 74 | 62 | 55 |
| 2g            | 175| 157| 87 | 60 | 41 | 30 | 25 |

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryFigure2forreviewonly.docx
- RevisedSupplementaryFigure1.docx
- SupplementaryTable1.docx